Skip to main content
SpringerLink
Log in

Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is known for its high rate of recurrence and poor prognosis, which makes it necessary to identify new predictive markers for HCC and to explore the underlying mechanism(s). Emerging evidence suggests that the proteoglycan serglycin (SRGN) might play a crucial role in tumor metastasis. However, currently, the function of SRGN in HCC remains unknown. Here, we evaluated the expression pattern of SRGN in 127 HCC specimens and their adjacent, non-tumorous tissues using immunohistochemical assays. We observed that SRGN was significantly upregulated in HCC tissues. Elevated expression levels of SRGN were detectable in 72/127 (56.7 %) of the HCC specimens and in 4/127 (3.1 %) of adjacent non-tumorous tissues (p < 0.001). Further correlation analysis demonstrated that the increased expression of SRGN was positively associated with HBV infection, GGT level, vascular invasion, advanced BCLC stage and early recurrence (p < 0.05). Increased SRGN expression correlated with unfavorable prognosis in HCC patients. In multivariate analyses, SRGN expression levels were found to represent an independent predictor for overall survival (p = 0.002) and time to recurrence (p = 0.010) of HCC patients. Furthermore, the elevated expression of SRGN in the HCC tissues was accompanied by elevated levels of vimentin and the absence of E-cadherin. Similarly, the reduced expression of SRGN was accompanied by elevated levels of E-cadherin and the absence of vimentin. E-cadherin and vimentin are well-accepted biomarkers of the epithelial–mesenchymal transition (EMT), and the expression of SRGN might correlate with EMT. Our results demonstrate that the elevated expression of SRGN represents a crucial event in HCC patients that is indicative of poor clinical outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  2. Maluccio M, Covey A, et al. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62(6):394–9. doi:10.3322/caac.21161.

    Article  PubMed  Google Scholar 

  3. Zhu WW, Guo J, Guo L, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013;19(14):3944–54. doi:10.1158/1078-0432.CCR-12-3363.

    Article  CAS  PubMed  Google Scholar 

  4. Poon RT. Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. Hepatology. 2011;54(3):757–9. doi:10.1002/hep.24569.

    Article  PubMed  Google Scholar 

  5. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma–an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23(11):1535–47. doi:10.1111/j.1365-2036.2006.02932.x.

    Article  CAS  PubMed  Google Scholar 

  6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. doi:10.1056/NEJMoa0708857.

    Article  CAS  PubMed  Google Scholar 

  7. Chen J, Chan AW, To KF, et al. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3beta/beta-catenin signaling. Hepatology. 2013;57(6):2287–98. doi:10.1002/hep.26278.

    Article  CAS  PubMed  Google Scholar 

  8. Abdel-Rahman O, Abdel-Wahab M, Shaker M, et al. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol. 2013;30(3):655. doi:10.1007/s12032-013-0655-z.

    Article  PubMed  Google Scholar 

  9. Ronnberg E, Pejler G. Serglycin: the master of the mast cell. Methods Mol Biol. 2012;836:201–17. doi:10.1007/978-1-61779-498-8_14.

    Article  PubMed  Google Scholar 

  10. Woulfe DS, Lilliendahl JK, August S, et al. Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice. Blood. 2008;111(7):3458–67. doi:10.1182/blood-2007-07-104703.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Glenthoj A, Cowland JB, Heegaard NH, et al. Serglycin participates in retention of alpha-defensin in granules during myelopoiesis. Blood. 2011;118(16):4440–8. doi:10.1182/blood-2011-06-362947.

    Article  PubMed  Google Scholar 

  12. Henningsson F, Hergeth S, Cortelius R, et al. A role for serglycin proteoglycan in granular retention and processing of mast cell secretory granule components. FEBS J. 2006;273(21):4901–12. doi:10.1111/j.1742-4658.2006.05489.x.

    Article  CAS  PubMed  Google Scholar 

  13. Pejler G, Abrink M, Wernersson S, et al. Serglycin proteoglycan: regulating the storage and activities of hematopoietic proteases. BioFactors (Oxford, England). 2009;35(1):61–8. doi:10.1002/biof.11.

    Article  CAS  Google Scholar 

  14. Veugelers K, Motyka B, Frantz C, et al. The granzyme B-serglycin complex from cytotoxic granules requires dynamin for endocytosis. Blood. 2004;103(10):3845–53. doi:10.1182/blood-2003-06-2156.

    Article  CAS  PubMed  Google Scholar 

  15. Grujic M, Christensen JP, Sorensen MR, et al. Delayed contraction of the CD8 + T cell response toward lymphocytic choriomeningitis virus infection in mice lacking serglycin. J Immunol. 2008;181(2):1043–51.

    Article  CAS  PubMed  Google Scholar 

  16. Kolset SO, Tveit H. Serglycin–structure and biology. Cell Mol Life Sci. 2008;65(7–8):1073–85. doi:10.1007/s00018-007-7455-6.

    Article  CAS  PubMed  Google Scholar 

  17. Meen AJ, Oynebraten I, Reine TM, et al. Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1. J Biol Chem. 2011;286(4):2636–47. doi:10.1074/jbc.M110.151944.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Ho HC, McGrath KE, Brodbeck KC, et al. Serglycin proteoglycan synthesis in the murine uterine decidua and early embryo. Biol Reprod. 2001;64(6):1667–76.

    Article  CAS  Google Scholar 

  19. Schick BP, Ho HC, Brodbeck KC, et al. Serglycin proteoglycan expression and synthesis in embryonic stem cells. Biochim Biophys Acta. 2003;1593(2–3):259–67.

    Article  CAS  PubMed  Google Scholar 

  20. Niemann CU, Kjeldsen L, Ralfkiaer E, et al. Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2007;21(12):2406–10. doi:10.1038/sj.leu.2404975.

    Article  CAS  Google Scholar 

  21. Scully OJ, Chua PJ, Harve KS, et al. Serglycin in health and diseases. Anat Rec. 2012;295(9):1415–20. doi:10.1002/ar.22536.

    Article  CAS  Google Scholar 

  22. Skliris A, Labropoulou VT, Papachristou DJ, et al. Cell-surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases. FEBS J. 2013;280(10):2342–52. doi:10.1111/febs.12179.

    Article  CAS  PubMed  Google Scholar 

  23. Li XJ, Ong CK, Cao Y, et al. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 2011;71(8):3162–72. doi:10.1158/0008-5472.CAN-10-3557.

    Article  CAS  PubMed  Google Scholar 

  24. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(18):2586–93. doi:10.1200/jco.2006.09.4565.

    Article  Google Scholar 

  25. Kwon JH, Kim J, Park JY, et al. Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma. Clin Cancer Res. 2010;16(22):5511–21. doi:10.1158/1078-0432.ccr-10-0825.

    Article  CAS  PubMed  Google Scholar 

  26. Ren N, Wu JC, Dong QZ, et al. Association of specific genotypes in metastatic suppressor HTPAP with tumor metastasis and clinical prognosis in hepatocellular carcinoma. Cancer Res. 2011;71(9):3278–86. doi:10.1158/0008-5472.can-10-3100.

    Article  CAS  PubMed  Google Scholar 

  27. Hao K, Luk JM, Lee NP, et al. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer. 2009;9:389. doi:10.1186/1471-2407-9-389.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711. doi:10.1093/jnci/djn134.

    Article  PubMed  Google Scholar 

  29. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90. doi:10.1016/j.cell.2009.11.007.

    Article  CAS  PubMed  Google Scholar 

  30. Liu FY, Deng YL, Li Y, et al. Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma. Med Oncol. 2013;30(1):425. doi:10.1007/s12032-012-0425-3.

    Article  PubMed  Google Scholar 

  31. Zhao D, Yang K, Tang XF, et al. Expression of integrin-linked kinase in adenoid cystic carcinoma of salivary glands correlates with epithelial-mesenchymal transition markers and tumor progression. Med Oncol. 2013;30(3):619. doi:10.1007/s12032-013-0619-3.

    Article  PubMed  Google Scholar 

  32. Schick BP. Serglycin proteoglycan deletion in mouse platelets: physiological effects and their implications for platelet contributions to thrombosis, inflammation, atherosclerosis, and metastasis. Prog Mol Biol Transl Sci. 2010;93:235–87. doi:10.1016/s1877-1173(10)93011-1.

    Article  CAS  PubMed  Google Scholar 

  33. Theocharis AD, Seidel C, Borset M, et al. Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J Biol Chem. 2006;281(46):35116–28. doi:10.1074/jbc.M601061200.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Supported by grants from National Natural Science Foundation of China (No. 81201634).

Conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hepatobiliary Oncology, Affiliated Tumor Hospital, Guangzhou Medical University, 78 Hengzhigang Road, Guangzhou, 510095, Guangdong, China

    Lu He, Xinke Zhou, Yunqiang Tang & Jian Hong

  2. Cancer Institute, Central South University, Changsha, Hunan, China

    Chen Qu

  3. Department of Pathophysiology, Affiliated Tumor Hospital, Guangzhou Medical University, Guangzhou, 510095, Guangdong, China

    Qiong Zhang

Authors
  1. Lu He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinke Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chen Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yunqiang Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qiong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jian Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xinke Zhou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, L., Zhou, X., Qu, C. et al. Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients. Med Oncol 30, 707 (2013). https://doi.org/10.1007/s12032-013-0707-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0707-4

Keywords

Search

Navigation